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The steady increase in incidence of chronic respiratory disease (CRD) now constitutes a serious
public health problem. CRDs are often underdiagnosed and many patients are not diagnosed
until the CRD is too severe to prevent normal daily activities. The prevention of CRDs and
reducing their social and individual impacts means modifying environmental and social factors
and improving diagnosis and treatment. Prevention of risk factors (tobacco smoke, allergens,
occupational agents, indoor/outdoor air pollution) will significantly impact on morbidity and
mortality.
The Italian Ministry of Health (MoH) has made respiratory disease prevention a top priority
and is implementing a comprehensive strategy with policies against tobacco smoking, indoor/
outdoor pollution, obesity, and communicable diseases. Presently these actions are not well22 836718/846549; fax: þ39 0322 869950.
edico.it (C.F. Donner).
1 Elsevier Ltd. All rights reserved.
2 G. Laurendi et al.coordinated. The Global Alliance against Chronic Respiratory Diseases (GARD), set up by the
World Health Organization, envisages national bodies; the GARD initiative in Italy, launched
11/6/2009, represents a great opportunity for the MoH.
Its main objective is to promote the development of a coordinated CRD program in Italy.
Effective prevention implies setting up a health policy with the support of healthcare profes-
sionals and citizen associations at national, regional, and district levels. What is required is
a true inter-institutional synergy: respiratory diseases prevention cannot and should not be
the responsibility of doctors alone, but must involve politicians/policymakers, as well as
the media, local institutions, and schools, etc. GARD could be a significant experience and
a great opportunity for Italy to share the GARD vision of a world where all people can
breathe freely.
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Today the National Health System is responding to new
needs for assistance characterized by the high prevalence
of chronic conditions that require long term continuous
care and the use of strategies to stabilize acute patholog-
ical situations and improve patients’ quality of life. A new
and different equilibrium must be sought in which the
patient, not the disease, is at the heart of the system. We
need to create new partnerships with the various stake-
holders - not only those directly involved in the medical
world - for an extensive interchange amongst all partners,
highlighting the role of the different associations as
a reference point. The person and not the disease must be
at the center of the care pathway. This signifies the need
for integration between hospitals and the local community,
preserving the role of the network specialist and reinforcing
the role of general practitioners (GPs) and pediatricians.
In the last decade several European countries have
undertaken national initiatives to achieve these goals. In
Finland, for instance, programs on COPD and asthma have
been developed. The National Asthma Program was
undertaken from 1994 to 2004 to improve asthma care and
prevent increasing costs. The main goal was to lessen the
burden of asthma on individuals and society. Data show that
the incidence of asthma is still increasing but that itsburden has decreased considerably and that it is possible to
reduce asthma morbidity and its impact on both individuals
and society, e.g. the number of hospital days has fallen by
54% from 110,000 in 1993 to 51,000 in 2003 (69% in relation
to the number of asthmatics), with the trend still down-
wards. In 1993, 7212 patients of working age received
a disability pension from the Social Insurance Institution
compared with 1741 in 2003. The absolute decrease was
76% and 83% in relation to the number of asthmatics. The
increasing cost of asthma (compensation for disability,
drugs, hospital care, and outpatient doctor visits) ended: in
1993 the costs were V 218 million; they fell to V 213.5
million in 2003 (cost per patient per year decreased by
36%).1 The Finnish National Program for Chronic Bronchitis
and COPD (1998e2007) was set up with similar aims. Its
major strengths were: multidisciplinary strategies and web-
based guidelines in nearly all primary healthcare centers
around the country. The prevalence of COPD remained
unchanged. Smoking decreased in males from 30% to 26%
and in females from 20% to 17%. Significant improvements
in the quality of spirometry were obtained. Hospitalization
decreased by 39.7% and COPD costs were 88% lower than
had been anticipated for earlier investigations.2
In England, the Department of Health (DH) recently
introduced a number of service frameworks for major health
problems, such as heart disease and diabetes, to reduce
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results. The same methodology of reviewing evidence,
setting standards and markers of good practice in conjunc-
tion with professionals, managers and service users was used
to introduce a national strategy for COPD. A recorded
prevalence of COPD was estimated from primary care
disease registers of 1.5% of the total registered population
(all ages) against a calculated underlying prevalence of 9.7%
(DH, 2008). Deprived urban populations had the highest
prevalence and highest underdiagnosis of COPD, and
accounted for a considerable part of the life expectancy gap
compared to England as a whole (DH, 2007), representing
a major challenge for DH in terms of diagnosing and opti-
mally treating the missing millions. The COPD strategy has,
at the core of its standards for the NHS, the aspiration to
promote good lung health, helping individuals and others to
reduce risks, early identification and accurate diagnosis
including severity, regular review and promotion of self
care, access to pulmonary rehabilitation, proactive
management of exacerbations, early assessment for surgical
intervention and supported palliative and end of life care.
Implementation is being supported through the develop-
ment of a competent workforce and the evaluation of
patient reported outcome measures and quality indicators.3
In Italy respiratory diseases, after cardiovascular and
malignant diseases, are the 3rd leading cause of death and,
given the aging population, their prevalence is expected to
rise in the next decades.4 The fight against respiratory
diseases is primarily on two fronts: primary prevention (e.g.
through interventions against smoking and pollutants in the
home and workplace) and secondary prevention (e.g. early
diagnosis). Equally important is information to patients and
family members, who must be trained to recognize the
disease characteristics, follow the prescribed treatment
correctly, react promptly in the case of exacerbation and
utilize the home care services provided.
The 55th World Health Assembly, recognizing the enor-
mous suffering caused by chronic diseases, called for
a global effort to combat them through international alli-
ances and partnerships to coordinate the mobilization of
resources, formulate a defense strategy, and strengthen
research capacity and collaboration.5 The Global Alliance
Against Chronic Respiratory Diseases (GARD) was set up in
2004 to effectively address the problems caused by chronic
respiratory disease (CRD). GARD is a voluntary alliance at
national and international level made up of organizations,
institutions and agencies working for the common goal of
improving global lung health.6,7 GARD has the following
working goals:
1. to develop national programs of prevention and control
of CRDs, starting with health education campaigns and
a better knowledge of epidemiology, impact, and
relative risk factors;
2. to provide training and continuing education on
prevention and treatment of CRDs, disseminating the
existing guidelines;
3. to facilitate access to essential treatments and favor
adherence to long term treatment, including drug
treatment and pulmonary rehabilitation, particularly
amongst disadvantaged sectors of the population.The Alliance is part of the World Health Organization’s
(WHO) activities for prevention and control of non
communicable diseases and is based on: estimating the
population’s needs and interventions, defining and adopt-
ing policies, and identifying the stages of implementation
of policies. GARD is working to make CRDs a public health
priority in all countries and to ensure that governments, the
media, citizens, patients, health professionals and all
stakeholders are aware of the scope of this problem.
A national planning policy in all countries is essential in
order to assign the right priorities and ensure that resources
are allocated efficiently. Therefore, the added value of
GARD is to provide a collaborative network through which
the parties can join forces to achieve results that could not
be obtained alone and to improve the coordination
between governmental and non-governmental programs to
avoid duplicating efforts and wasting resources. The GARD
action plan 2008e2013 is an instrument of WHO’s global
strategy for prevention and control of chronic diseases.8
GARD implements actions at local level through the estab-
lishment of national alliances.
Within this context, the Italian GARD (GARD-I) was set up
to develop a strategy for prevention and care of respiratory
diseases in Italy. GARD-I is a voluntary national alliance e
made up of institutions, scientific societies, patients’
associations and other potential partners working in the
respiratory field. The overall objective of each national
GARD body, based on the rules established by the interna-
tional GARD, is to reduce the incidence, morbidity and
mortality of respiratory diseases in the long term through
an integrated approach.8 With regard to Italy, GARD-I will
discuss and identify actions, strategies and tools according
to those defined by the National Health planning.
The fields of activity fixed for the first two years are:
1) Prevention of respiratory disease in schools
2) Smoke and home environment
3) Early diagnosis
4) Continuity of care
5) Education/Training
Epidemiology of respiratory diseases in Italy
Assessments of mortality/morbidity for COPD often include
chronic bronchitis, emphysema and asthma. Chronic bron-
chitis and asthma affect more than 20% of the elderly
population (>64 years). Mortality from chronic bronchitis,
emphysema and asthma is particularly high in Liguria,
Piedmont and Valle d’Aosta (about 36/100,000), while the
regions with the lowest rates are Trentino Alto Adige,
Veneto and Lazio (23e24/100,000).9 From 1990 to 2002
there was an almost continuous decline in mortality for
chronic bronchitis, emphysema and asthma in males. In
females, the decline was arrested in 2000; however 2002
saw an increase. From 2002 to 2003, the mortality rate
further increased in females (8e12/100,000), and also
increased in males (26e36/100,000) (European mortality
database of ’Health for All’-MDB-HFA 2008). In contrast,
deaths from asthma alone decreased continuously from
1995 (1500 deaths) to 2006 (513, 41% males). In 2006, there
were 20,257 deaths from chronic lower respiratory
Figure 2 People reporting asthma in Italy, by region -
Standardised rates per 100 people e Years 2004e2005 (Source:
State of health and use of health services, ISTAT 2008).
4 G. Laurendi et al.diseases.10 But as mortality data refer only to the primary
cause of death as reported on death certificates, there is
a possible underestimation of mortality due to COPD. An
Italian study found that COPD, as a contributing cause of
death, accounts for 62% of total mortality. This doubles the
mortality estimate from COPD as the main cause.11
With regard to morbidity, in 2004 COPD was the 4th
leading cause of chronic disease in Italy, affecting 4 million
people. After arthrosis/arthritis, hypertension and osteo-
porosis, COPD together with diabetes has the highest
increase of incidence (about 6%) in the elderly.12 More than
4 in 100 people claim to have chronic bronchitis/emphy-
sema (Figure 1) and more than 3 in 100 have asthma
(Figure 2) (ISTAT 2008).
Overall, underdiagnosis of COPD in Italy ranges from 25
to 50% and epidemiological investigations conducted in the
Po river delta and in Pisa-Cascina confirm and extend
international observations.13 The lack or delay of diagnosis
affects the timing of therapeutic intervention, contributing
to the evolution toward more severe disease. The last
annual report by the Ministry of Health14 on hospitalization,
based on hospital discharge records (HDR), shows that in
2005 COPD was the 2nd leading cause of hospitalization for
acute respiratory disease (after pneumonia/pleurisy), fol-
lowed in 3rd place by respiratory failure/pulmonary edema
and in 4th place by asthma/bronchitis. From 2000 to 2005,
the number of hospitalizations for COPD and asthma/
bronchitis decreased, while there was a very obvious
increase in hospitalizations for respiratory failure/pulmo-
nary edema (Figure 3). The decline of admissions for COPD
may be a consequence of compilation of the SDO (hospital
discharge form), in that COPD patients hospitalized for
respiratory failure (i.e. the prevalent cause for hospital0 1 2 3 4 5 6 7 8
Trentino-Alto Adige
Friuli-Venezia Giulia
Veneto
Liguria
Toscana
Piemonte
Lombardia 
Campania
Emilia-Romagna
Sicilia   
Puglia
Lazio
Valle d'Aosta
Abruzzo
Marche 
Sardegna
Basilicata
Molise
Calabria
Umbria 
Figure 1 People reporting chronic bronchitis/emphysema in
Italy, by region e Standardised rates per 100 people e Years
2004e2005 (Source: State of health and use of health services,
ISTAT 2008).admission, simple COPD normally being managed in an
outpatient regime) may have been encoded into the DRG
(diagnosis-related group) of the latter and not COPD, so
permitting a higher reimbursement by the NHS. Moreover,
in many hospitalized COPD patients respiratory failure is
the first diagnosis with COPD associated, hence the DRG is
87 and not 88.15e17
Important data on the prevalence of asthma in Italy
emerge from the ECRHS study (The European Community
Respiratory Health Survey),18 epidemiologic studies of the
Po Delta and Pisa16 for adults, and the study SIDRIA (Italian
studies on respiratory disorders in childhood and the envi-
ronment, under the international protocol ISAAC) for
children.19e22 The prevalence of asthma in Italy, lower than
in many other European countries, ranges from 3.3 to 5.3%
in adults and 10% in children. These data place Italy in a low
position in the European ranking. The only data on general
population samples are derived from surveys conducted by
the Institute of Clinical Physiology CNR (Pisa) in the Po Delta
and Pisa. These surveys indicate a prevalence of asthma
ranging from 5.3 to 6.5%, of chronic bronchitis from 1.5 to
2.5% (chronic sputum from 11.7 to 14.4%), and of emphy-
sema from 1.2 to 3.6%.13
A recent population-based cross-sectional epidemiologic
survey of asthma and COPD was carried out in an adult
representative national sample of 55,500 subjects affected
by asthma and 25,762 subjects aged 14 years with COPD,
selected to be representative of the whole Italian pop-
ulation. The asthma/COPD ratio in the general population
was 2.16. The odds ratio (OR) of developing asthma
decreased with age in both men and women, but in the first
age group (15e34 years) it was higher in men (1.69 vs. 1.00)
although it became <1 from 35 years old and up in men and
from 75 years old and up in women. On the contrary, the OR
020000
40000
60000
80000
100000
120000
140000
160000
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
COPD
Lung Cancer
Pneumonia/Pleurisy
Bronchitis/Asthma
Interstitial lung diseases
Pulmonarry embolism
Pleural effusion
Pneumothorax
Respiratory failure/ 
Pulmonary edema
Figure 3 Time trend of hospitalizations (number) for respiratory diseases (Source: Annual report on the activities of hospital-
2005, Ministry of Health 2007).
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both men and women and progressively increased with age
(in the group 75e84 years it was 6.16 in men and 4.07 in
women).23
GARD-I
GARD-Italy (GARD-I) was set up in June 2009, under the
umbrella of GARD International,24 with 38 scientific socie-
ties and associations as foundation members. This high
number represents a peculiarity of the Italian situation,
with 3 major scientific respiratory societies (one hospital-
based, one academic and one interdisciplinary) which
cooperate in preparing statements, guidelines, and carrying
out scientific projects. The other entities consist, on one
hand, of small societies with a very narrow target (alpha1
antitrypsin deficiency, pediatric pulmonology, respiratory
allergic diseases etc.) and, on the other, of many patient
associations for specific diseases (only in the case of asthma
are they grouped into a large federation). The mission and
intent of GARD-I are indicated in the strategy paper
prepared by the Ministry of Health in collaboration with the
scientific societies and patient associations in the area of
respiratory disease. Each member of GARD-I in Italy accepts
unreservedly the strategy document and goals of the Alli-
ance expressed in it. The specific objectives are:
 building alliances
 creation of a database for respiratory diseases
 advocacy
 implementation of policies for health promotion and
prevention of respiratory disease (intervention on the
population)
 implementation of strategies for management of
chronic respiratory diseases (intervention on the
individual)
 implementation of policies across sectors.
With regards to the Italian context, GARD-I identifies and
discusses its actions, strategies and instruments inreference to the issues defined by the National Health Plan,
the National Prevention Plan or any other measure of
health planning. GARD-I has set up its own rules of proce-
dure, and is divided into a General Assembly and an Exec-
utive Committee and also operates through working groups.
The Alliance is not financed by the Ministry of Health.
Members and experts participate voluntarily in meetings of
the Assembly, the Executive Committee and Working
Groups. Publications (any form, whether printed, video or
electronic) on the activities of GARD-I, including those
written by experts or members, must receive authorization
from the Ministry of Health before their release. The
Ministry of Health is assigned the role of technical leader-
ship and secretariat of GARD-I.
GARD-I represents a real opportunity for developing
a comprehensive strategy of prevention and care of respi-
ratory disease adapted to the Italian context. The objec-
tives can be achieved only if fragmentation and lack of
coordination can be avoided. Even though the Alliance has
just recently been created, it accepts the challenge for
a global strategy and a shared vision in the prevention and
care of respiratory diseases worldwide.GARD-I: working groups so far implemented
Prevention of respiratory diseases at school
The prevention, management and control of diseases
related to indoor living spaces frequented by children
(schools, kindergartens) are priority objectives of the
strategy for the environment and health of the European
Union. The strategy, also known as “SCALE” (Science,
Children, Awareness, Legal instrument, Evaluation),
supports the importance of protecting first and foremost
children’s health from environmental threats. Such an
investment is essential to ensure an adequate social and
economic development. The strategy’s goals are also laid
down in the European Plan of Action for the Environment
and Health 2004e2010, which was an important contribu-
tion to the 4th Intergovernmental Conference on
6 G. Laurendi et al.Environment and Health, organized in Budapest by the WHO
European Region.
In 2004e2005 the European study HESE (Health Effects
of School Environment) collected comparable information
on indoor air quality (IAQ) and on respiratory health of more
than 600 pupils from a sample of 21 schools in Europe (Italy,
France, Sweden, Denmark and Norway). Samples were ob-
tained using common standardized procedures. The final
report (HESE Final Report, 2006) showed that, in general,
air quality in schools (46 classrooms tested) is poor, with
regard to the measurement of PM10 (particulate matter
consisting of particles smaller than 10 mm), CO2, mold and
allergens. The analysis showed that effects on respiratory
health of children may be attributable to exposure to high
levels of PM10 and CO2 in schools. In Italy, children spend
from 4 to 8 h a day in school buildings for at least 10 years.
The studies conducted so far show that Italian school
buildings often have serious sanitation problems due to
poor quality of buildings, lack of maintenance and problems
related to poor air conditioning (Circular No. 85/2001 of the
MIUR - monitoring of safety at school - data 2001). There
are not yet official guidelines on air quality in schools. An
important initiative in this area is the project “Indoor Air
Pollution in Schools” developed by EFA (European Federa-
tion of Allergy and Airways Diseases Patients Associations)
which receives financial assistance from the European
Commission.
Smoke and home environment
Italian households spend nearly all their time (90%) indoors
(home, public buildings, shopping centers). Hence the
importance of attention to indoor pollution. One of the
main sources of indoor pollutants is cigarette smoke.25
Tobacco smoke is generally divided into: active smoke
and passive smoke, with a small difference in the physical-
chemical composition and degree of disease risk entailed. It
is estimated that non-smokers exposed to passive smoke
are actually forced to “smoke” the equivalent of 1e3
cigarettes daily. This implies the risk of disease that,
although less than active smoking in terms of individual
cumulative exposure, concerns a large portion of the pop-
ulation (65% of non-smokers, i.e. about 20 million people
are at risk).26 Risk, in this case unwanted and preventable,
often falls upon people with pre-existing conditions and
who are subject to immediate consequences, as in the case
of asthmatics, children and pregnant women. Although
generally divided into two separate categories in terms of
physical-chemical composition, there are other major
differences between active and passive smoking. Many are
found in the smoke carcinogens (polycyclic hydrocarbons,
benzene, nitrosamines), irritants and allergens such as
formaldehyde, harmful gases such as carbon monoxide or
irritants such as sulfur oxides and nitrogen, in addition to
nicotine which is responsible for drug dependence. Like
active smoking, passive smoking has also been recently
classified as carcinogenic to humans. For both types of risk
there is the concept of a doseeresponse relationship: the
greater the amount of exposure, the greater the risk of
disease. Indoor cigarette smoke can cause very high
concentrations of fine particles, up to 100 times above the
legal limits allowed for the external environment. ETS is
a true agent of pollution. According to ISTAT (NationalInstitute of Statistics), smoking of parents and other family
members strongly influences the behavior of the young.
Training in early diagnosis
The fight against respiratory diseases is carried out
primarily through interventions aimed at both primary
prevention (e.g. combating smoke and pollutants in the
living and work environment) and secondary. Equally
important is the information provided to patients and
family members, who must be trained to know the char-
acteristics of the disease, to follow the prescribed treat-
ment correctly and to react promptly in the case of
exacerbation.
The GP and family pediatrician play a major role in
prevention: the context of primary care is the local
community and its role is of fundamental importance in the
NHS. GPs and pediatricians need to be sensitized, educated
and updated on the importance of prevention and early
diagnosis in respiratory diseases.
Predictive medicine
CRDs represent a wide range of serious medical conditions
in chronic diseases and constitute a serious public health
problem, with important effects on patients’ quality of life
and serious but underestimated economic effects on fami-
lies, communities, and populations in general. We are all
exposed to risk factors for respiratory disease: environ-
mental risk factors (smoking, occupational exposure,
indoor and outdoor air pollution, social conditions, diet,
infections) and individual risk factors (genetic and family-
related) which, interacting with each other, determine
the onset of the disease. Prevention of these factors can
have a significant impact on morbidity and mortality.
This project aims to introduce predictive medicine into
the respiratory area. There are several definitions in the
literature of predictive medicine, each emphasizing one or
other aspect of the field of investigation. Here, predictive
medicine is intended as an individual approach, before
and/or after birth, that attempts to discover and evaluate
risk factors in probabilistic terms in order to prevent the
disease. Predictive medicine is probabilistic, individual and
as such allows to determine the risk profile of each person,
to monitor progress and implement appropriate preventive
measures. Predictive medicine is an approach that requires
knowledge and innovation in current patterns of medical
thinking.
Continuity of care
In epidemiological terms, the CRDs with the greatest weight
include asthma, COPD, occupational respiratory diseases,
allergic rhinitis and allergies, sinusitis, sleep apnea
syndrome, and pulmonary hypertension. CRDs represent
a major part of global disability-adjusted life years (DALYs).
Hospital discharge records (HDR) show that in 2004 there
were70,343hospitalizations forbronchitis andasthma (11.3%
of total admissions for respiratory causes), which led to an
average stay of 6.5 days. There are no significant differences
betweenmales and females in the number of hospitalizations
(36,514 males and 38,290 females) or in average number of
hospital days (6.2 and 6.8 in males and females).
To improve the continuity of care, models of integrated
management need to be developed. Secondly, efforts must
Global alliance against chronic respiratory diseases in Italy (GARD-Italy) 7be made to ensure the appropriateness of diagnosis and of
the treatment provided. Profiles of nursing care based on
a multidisciplinary approach must be developed to ensure
a continuity between the actions of prevention, care and
rehabilitation, with cross-sectoral interventions embracing
both the health and social sectors, in which the family has
a key role in the care pathway.Integration with national programs of the Ministry
of Health
The Ministry of Health works in the context of devolution in
accordance with the reform of the Constitution (Article V of
the 2001 Amendment). The state’s role in health today is
essentially to guarantee equity and health rights, as
enshrined in Article 32 of the Constitution, by:
1. ensuring for all fairness, quality, efficiency and trans-
parency of the system, with proper and adequate
communication;
2. highlighting inequalities and inequities and promoting
corrective actions and improvements;
3. collaborating with the Regions to assess the reality and
improve health;
4. planning innovation and change and confronting the
issues that threaten public health.
The National Health Plan (NDP) 2006e200827 identified
four major diseases: cancer, cardiovascular diseases, dia-
betes and respiratory diseases. These latter are in our country
the 3rd leading cause of death and of these, COPD is
responsible for about 50% of deaths, males being most
affected. To these epidemiological data it is important to add
the significant social costs linked to respiratory disease (e.g.
lost productivity for sick leave, absence from school and
consequent parental absence fromwork for child care, etc.).
Following the recognition of the impact of respiratory
diseases, theNDPhas identified the followingpriority actions:
- cross-sector programs to reduce environmental and
occupational risk;
- measures to inform and educate individuals and fami-
lies on positive behaviors to combat the main causative
agents and reduce risk;
- information, communication and promotion of early
diagnosis, involving in particular GPs and pediatricians;
- prevention and treatment of disability.
Although there are effective preventive measures, CRDs
are underdiagnosed, undertreated and inadequately pre-
vented. The National Plan of Prevention,28 approved by the
State-Regions Agreement, lists the prevention of respira-
tory diseases as a priority for the years 2010e2012. Among
actions already under development, the Ministry recently
participated in an advisory role with the National Agency
for Regional Health Services (AGENAS) in drafting a State-
ment on Integrated Clinical Management of COPD prepared
by a working group composed of the 3 major respiratory
scientific societies (AIMAR, AIPO and SIMeR) and the Italian
Society of GPs (SIMG). This document, which aims to offer
a practical care model for all healthcare professionalsinvolved in COPD management, was presented at the 2011
ERS Congress in Amsterdam, while the Ministry will coor-
dinate its implementation in Italy.
Conclusions
The WHO has long promoted an integrated approach to
prevention and treatment of all chronic diseases. An inte-
grated approach combining the prevention and treatment
of CRDs (similar to what has been done for a long time for
heart disease, cerebral vascular and other chronic diseases)
is necessary as these diseases share many risk factors and
call for a similar response from the National health
services. This approach is summarized in the recent report
of WHO “Preventing chronic diseases: a vital investment"29
and represents not only the best form of prevention and
diagnosis but also the most cost-effective one. GARD-I is an
essential step for creating a path to provide Italy with
a comprehensive strategy of prevention and assistance,
sharing that journey with scientific societies and patient
organizations.
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